COVID-19 and chronic rhinosinusitis: management and comorbidity - what have we learned?
Expert Rev Clin Immunol
; 19(11): 1399-1406, 2023.
Article
em En
| MEDLINE
| ID: mdl-37551742
ABSTRACT
INTRODUCTION:
Approximately 5%-12% of the population worldwide suffer from chronic rhinosinusitis (CRS). CRS is defined as a chronic respiratory disease and is considered to be a risk factor for COVID-19 patients. AREAS COVERED A non-systematic literature research was conducted on COVID-19 and treatment options for CRSwNP. The latest international publications in medical databases, international guidelines, and the internet were reviewed. Since there were no publications on all aspects of this topic during the pandemic, we included our own experience in this report. Based on the conducted literature research in addition to our previously reported experience, we discuss the treatment of CRSwNP during the COVID-19 pandemic and what can be taken for future pandemics. EXPERT OPINION Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Indications for surgical treatment of CRS should be critically evaluated and reserved for patients with complications and those with no other treatment options. For this purpose, COVID-19 status should be known if possible and, in case of unclear status (emergency), using appropriate personal protective equipment. Systemic corticosteroids should be avoided were possible. Biological treatment should be continued under careful monitoring in uninfected patients and should be temporarily interrupted during COVID-19 infection.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Guideline
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article